Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 7Endocrine 7CNS 2Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 47Pancreatic Neoplasms 43Neoplasm Metastasis 20Carcinoma, Hepatocellular 20Lung Neoplasms 15Ovarian Neoplasms 14Colonic Neoplasms 14Rectal Neoplasms 12Stomach Neoplasms 11Prostatic Neoplasms 11Melanoma 11Cholangiocarcinoma 11Carcinoma, Renal Cell 10Breast Neoplasms 10Sarcoma 8Lymphoma, Non-Hodgkin 8Glioma 8Carcinoma, Non-Small-Cell Lung 8Neuroblastoma 7Hepatoblastoma 7Esophageal Neoplasms 7Barrett Esophagus 7Anus Neoplasms 7Wilms Tumor 6Uterine Cervical Neoplasms 6Medulloblastoma 6Gastrointestinal Neoplasms 6Ependymoma 6Central Nervous System Neoplasms 6Adenocarcinoma Of Esophagus 6

Interventions

Everolimus 7lutetium Lu 177 dotatate 4lanreotide 4Sunitinib 4Temozolomide 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Capecitabine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3copper dotatate CU-64 2amino-acid, glucose, and electrolyte solution 2Quality of Life 2FAPI-46 2veliparib 1tivozanib 1tislelizumab 1telotristat ethyl 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1pembrolizumab 1pasireotide 1gallium Ga 68 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Specimen Handling × Gastrointestinal × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡